Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Laboratory Corporation of America Holdings / Equity Bottom-Up

Laboratory Corporation of America Holdings (LH US)

Laboratory Corporation of America Holdings

<ul><li>Labcorp Holdings has added another asset to its expanding laboratory network through the acquisition of MLM Medical Labs, a global central and specialty laboratory provider with operations in the U.S., Germany, and South Africa.</li><li>Financial terms were not disclosed, but the strategic direction is consistent with Labcorp’s recent operating priorities.</li><li>In the second quarter of 2026, the company reported 5.8% enterprise revenue growth, 70 basis points of adjusted operating margin expansion, and 14.9% adjusted EPS growth, while its Biopharma Laboratory Services business benefited from continued strength in Central Laboratories.</li></ul>

Labcorp Holdings has added another asset to its expanding laboratory network through the acquisition of MLM Medical Labs, a global central and specialty laboratory provider with operations in the U.S., Germany, and South Africa.Financial terms were not disclosed, but the strategic direction is consistent with Labcorp’s recent operating priorities.In the second quarter of 2026, the company reported 5.8% enterprise revenue growth, 70 basis points of adjusted operating margin expansion, and 14.9% adjusted EPS growth, while its Biopharma Laboratory Services business benefited from continued strength in Central Laboratories.

Labcorp Acquisition Of MLM Medical Labs Strengthens Its Central Lab Ambitions!

<ul><li>Labcorp Holdings reported its financial results for the second quarter of 2026, demonstrating modest growth and operational improvements amid a dynamic healthcare testing environment.</li><li>The company’s consolidated revenue increased by approximately 6% to $3.7 billion compared to the prior year, driven by both organic growth and contributions from acquisitions.</li><li>Adjusted earnings per share (EPS) rose nearly 15% to $4.99, supported by margin expansion and operating efficiencies.</li></ul>

Labcorp Holdings reported its financial results for the second quarter of 2026, demonstrating modest growth and operational improvements amid a dynamic healthcare testing environment.The company’s consolidated revenue increased by approximately 6% to $3.7 billion compared to the prior year, driven by both organic growth and contributions from acquisitions.Adjusted earnings per share (EPS) rose nearly 15% to $4.99, supported by margin expansion and operating efficiencies.

LH US - Labcorp Holdings’ $1.36 Billion Cash Flow Path — The Earnings Engine Is Strengthening!

<ul><li>Laboratory Corporation of America Holdings reported financial results for the first quarter of 2026 showing a moderate improvement in revenue, margins, and earnings per share.</li><li>The company’s enterprise revenue increased by approximately 6% to $3.5 billion, supported by organic growth, acquisitions, and favorable foreign currency impacts.</li><li>Adjusted operating margins expanded by over 30 basis points to 14.4%, while adjusted earnings per share rose 11%.</li></ul>

Laboratory Corporation of America Holdings reported financial results for the first quarter of 2026 showing a moderate improvement in revenue, margins, and earnings per share.The company’s enterprise revenue increased by approximately 6% to $3.5 billion, supported by organic growth, acquisitions, and favorable foreign currency impacts.Adjusted operating margins expanded by over 30 basis points to 14.4%, while adjusted earnings per share rose 11%.

LH US - Labcorp Faces Medicare Reform Pressure As Specialty Testing Growth Accelerates!

<ul><li>Labcorp Holdings reported strong financial performance for the fourth quarter and full year 2025, with notable advancements across various strategic priorities.</li><li>The company saw revenue growth of over 7% for the year, with adjusted earnings per share (EPS) increasing by 13% and margins expanding by more than 50 basis points.</li><li>The fourth quarter revenue increased 6%, with adjusted EPS up 18%, indicating robust performance.</li></ul>

Labcorp Holdings reported strong financial performance for the fourth quarter and full year 2025, with notable advancements across various strategic priorities.The company saw revenue growth of over 7% for the year, with adjusted earnings per share (EPS) increasing by 13% and margins expanding by more than 50 basis points.The fourth quarter revenue increased 6%, with adjusted EPS up 18%, indicating robust performance.

LH US - Labcorp's BIGGEST Pressure Point Is 13.5% Early Development Decline

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). </li>
<li>Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).</li>
<li>With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). 
Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).
With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.


Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

United States

Laboratory Corporation of America Holdings is a clinical laboratory company that offers clinical laboratory tests used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. The Company develops specialty testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laboratory Corporation of America Holdings (LH US)

Labcorp Acquisition Of MLM Medical Labs Strengthens Its Central Lab Ambitions!

Labcorp Holdings has added another asset to its expanding laboratory network through the acquisition of MLM Medical Labs, a global central and...

Baptista Research

LH US - Labcorp Holdings’ $1.36 Billion Cash Flow Path — The Earnings Engine Is Strengthening!

Labcorp Holdings reported its financial results for the second quarter of 2026, demonstrating modest growth and operational improvements amid a...

Baptista Research

LH US - Labcorp Faces Medicare Reform Pressure As Specialty Testing Growth Accelerates!

Laboratory Corporation of America Holdings reported financial results for the first quarter of 2026 showing a moderate improvement in revenue,...

Baptista Research

LH US - Labcorp's BIGGEST Pressure Point Is 13.5% Early Development Decline

Labcorp Holdings reported strong financial performance for the fourth quarter and full year 2025, with notable advancements across various...

Baptista Research

Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

Mixed Signals in A.I. Names ($SOXX $CHAT $DRAM $WGMI); Bullish Outlook Intact $SPX $QQQ $IWM. $CHAT breaking above the 50-day MA likely signaling...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)